Mohamed A. Gouda, Clinical Fellow at the University of Texas MD Anderson Cancer Center, shared a post on X about a recent paper by Ujjwol Khatri et al. published in Cancer Letters:
“Following observations we previously reported on weight gain as a side effect to selective RET inhibitors (PMID: 37473872), now new data on associations independent of anti-tumor activity!”
Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model
Authors: Ujjwol Khatri et al.
